Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging

Published:2009-05-14 Issue:6 Volume:50 Page:974-981
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Dijkers Eli C.F.,Kosterink Jos G.W.,Rademaker Anna P.,Perk Lars R.,van Dongen Guus A.M.S.,Bart Joost,de Jong Johan R.,de Vries Elisabeth G.E.,Lub-de Hooge Marjolijn N.

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference39 articles.

1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

2. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

Cited by 303 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes;Cancer Treatment Reviews;2024-11

2. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer;Journal of Nuclear Medicine;2024-09-05

3. Development of 52Mn Labeled Trastuzumab for Extended Time Point PET Imaging of HER2;Molecular Imaging and Biology;2024-08-27

4. In Vitro Assessment of 177Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer;Pharmaceuticals;2024-06-05

5. Good practices for 89Zr radiopharmaceutical production and quality control;EJNMMI Radiopharmacy and Chemistry;2024-05-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP